Type of information:
Compound: therapies targeting ZnT8
Company: Mellitech (France) Janssen Pharmaceuticals - J&J (USA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Disease: metabolic diseases
* On June 24th, 2013, Mellitech SAS, a biopharmaceutical company pioneering innovative approaches to the selective modulation of the ZnT8 target, a zinc transporter involved in the insulin secretion pathway and in various metabolic diseases, has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. to discover, develop and commercialize therapies targeting ZnT8 for the treatment of metabolic diseases.
Mellitech is a spin-out from the CEA and the University of Joseph Fourier in Grenoble. The company is a leading player in the biology of ZnT8, a key pancreatic protein that enables the excretion of insulin from the beta cell. Focused on the application of ZnT8 science to diabetes, Mellitech is pursuing a program of discovery and development of treatments covering both type 1 and type 2 diabetes, and of an agent for imaging the functional beta cell mass.
Financial terms: Under the terms of the agreement, Janssen Pharmaceuticals will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Mellitech is eligible to receive development milestone payments as well as royalty payments on global sales. Further details of the financial terms were not disclosed.